Dexcom G7 15 Day Continuous Glucose Monitoring System

The Dexcom G7 15 Day is less a reinvention than a patient, incremental upgrade to a sensor that was already among the best regarded in continuous glucose monitoring. The headline change is endurance: up to 15 days of wear plus a 12-hour grace period, half again as long as the 10-day G7. Everything else — the small 32mm puck, waterproofing, minute-by-minute data, compatibility with Omnipod 5 and Beta Bionics iLet — reads as evolution rather than revolution.

That makes the audience fairly easy to identify. If you're an adult already living with a G7 and you resent the ritual of sensor changes, this is squarely aimed at you: fewer insertions, fewer warm-up gaps, more time for sites to recover. It is cleared for adults 18 and over at launch, so families managing pediatric diabetes are not part of this first wave. And with a US launch date of December 1, 2025 — pushed back from an earlier autumn target — anyone hoping to switch imminently has had to be patient.

One note on our confidence here: pricing has not been published, and the source material we worked from disagrees on something as basic as warm-up time, quoting both 27 and 60 minutes. Those are not trivial gaps for a product people wear continuously, and they temper how firmly we can call this a recommendation.

On accuracy, this is a genuinely strong device, but let's be honest about the magnitude of the improvement. An overall MARD of 8.0% against the 10-day G7's 8.2% is a rounding error in practical terms — nobody will feel that difference in their treatment decisions. The clinical validation is more persuasive than the headline number: 130 adults, more than 20,300 matched pairs, and 99.9% of readings falling in the safest zones of the Consensus Error Grid. That is the kind of result that earns trust. It is also worth noting the per-sensor MARD is 8.2%, and that a competing sensor is cited at 7.8%, so Dexcom is not running away with the accuracy crown here.

The figure that gives us most pause is Dexcom's own disclosure that 73.9% of sensors complete the full 15-day wear. Credit for publishing it — that is unusually candid — but it means roughly one sensor in four falls short. The value proposition of this product is built almost entirely on longevity, so a quarter of sensors not going the distance undercuts the central pitch, and without knowing the price or the replacement policy we cannot tell you whether the maths still works in your favour.

The AID story is promising but unfinished. Working with Omnipod 5 and iLet out of the gate covers a meaningful slice of pump users, but with Tandem compatibility still in development, some closed-loop users will need to wait rather than upgrade.

Our verdict: a solid, thoughtful iteration that will meaningfully reduce the admin burden of CGM for most adult users, held back from a higher score by an accuracy gain that is statistically real but practically negligible, a sensor completion rate that qualifies the main selling point, and the absence of pricing we'd need to judge value properly. We'd revisit this rating once cost and real-world reliability data are in.